ur colleague Dr. Greg Gores declared HEPATOL-OGY as a home for liver cancer manuscripts and described how this hot area of liver disease has grown in recent years. Clearly, liver cancer has grown from a minor topic to become one of the most competitive realms in our field. Several groups are investing efforts and resources to produce results, get grant support, and publish manuscripts. This enthusiasm affects both laboratory and clinical research, with major emphasis placed on the need to translate results from the bench to the bedside. The fancy current term is "translational research" but this concept has always been present: the objective of research in biomedical sciences is to improve human health, by either preventing or treating diseases. Not surprisingly, when more activity takes place in any given field, the number of ongoing studies and proposals increases. This translates into a larger number of manuscripts written to report the data obtained in such investigations. Increased attention to the field of one's own interest is always pleasant, but this causes a tight competition for manuscripts accepted in the journal that the authors feel is best suited for publishing their results. Obviously, if HEPATOLOGY presents itself as a home for liver cancer manuscripts (and data are there to support this statement), a steadily increasing number of articles fitting in this category are being submitted for peer review. Because of the limited capacity of the journal, an increase in submissions lowers the acceptance rate (this is now around 17% for original research manuscripts submitted to HEPATOLOGY). This law is common to all competitive journals, and in order to provide fair decisions to the submitting authors, a stringent policy that is consistent and selects only those contributions that provide relevant information must be in place. The material must be both novel and interesting, because it is not enough to be novel but not interesting or interesting but not novel.